Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment

by Jeffrey R. Curtis, Kevin Winthrop, Cathy O’Brien, Matladi N. Ndlovu, Marc de Longueville, Boulos Haraoui
Published 2017-12-01

Exposure–Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis

by Stéphane Paul, Hubert Marotte, Arthur Kavanaugh, Philippe Goupille, Tore K. Kvien, Marc deLongueville, Denis Mulleman, William J. Sandborn, Niels Vande Casteele
Published 2020-07-01